Design Therapeutics, Inc. (DSGN) Key Metrics
DSGN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $645.2M
- Enterprise value
- $568.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.8 10-yr median 1.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.69
DSGN key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDSGN valuation Price multiples at each fiscal year-end price.
DSGN returns How much profit the business earns on the capital it uses.
DSGN per-share figures Results divided by the shares outstanding at year-end.
DSGN financial health Debt, liquidity and how easily interest is covered.
DSGN efficiency & capital use Working capital cycle and where the cash goes.
DSGN valuation history
DSGN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DSGN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DSGN price vs earnings per share
DSGN key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $537.8M | $349.1M | $148.4M | $571.6M | $983.6M | — | — |
| Enterprise value | $319.4M | $106.0M | −$130.4M | $244.9M | $603.1M | — | — |
| Price / book | 2.5 | 1.4 | 0.5 | 1.7 | 2.6 | — | — |
| Earnings yield | −13.0% | −14.2% | −45.1% | −10.3% | −3.6% | — | — |
| Free cash flow yield | −10.1% | −12.4% | −39.6% | −9.1% | −3.1% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $9.38 | $6.17 | $2.65 | $10.26 | $21.41 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 |
| Earnings per share | −$1.22 | −$0.88 | −$1.19 | −$1.05 | −$0.77 | −$0.30 | −$0.08 |
| Operating cash flow per share | −$0.95 | −$0.76 | −$1.05 | −$0.92 | −$0.64 | −$0.32 | −$0.01 |
| Free cash flow per share | −$0.95 | −$0.77 | −$1.05 | −$0.94 | −$0.67 | −$0.32 | −$0.01 |
| Cash per share | $3.83 | $4.34 | $5.03 | $5.93 | $8.36 | $1.33 | $0.00 |
| Book value per share | $3.71 | $4.28 | $4.96 | $5.88 | $8.32 | −$0.42 | −$0.13 |
| Tangible book value per share | $3.71 | $4.28 | $4.96 | $5.88 | $8.32 | −$0.42 | −$0.13 |
| Capex per share | $0.00 | $0.01 | $0.00 | $0.02 | $0.03 | $0.00 | $0.00 |
| Debt per share | $0.03 | $0.04 | $0.05 | $0.07 | $0.08 | — | $0.03 |
| Shares outstanding | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M | 27.2M | 27.2M |
| Change in shares outstanding | +1.3% | +1.1% | +0.5% | +21.3% | +69.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −30.7% | −19.1% | −22.1% | −16.5% | −19.2% | — | — |
| Return on assets (ROA) | −29.2% | −18.3% | −21.2% | −16.0% | −16.6% | −45.2% | — |
| Return on tangible assets | −30.9% | −19.7% | −23.1% | −17.2% | −9.1% | −22.7% | — |
| Free cash flow margin | — | — | — | — | — | — | −16.7% |
| Financial health | |||||||
| Total debt | $1.5M | $2.3M | $3.0M | $3.7M | $3.6M | — | $695,000 |
| Cash & short-term investments | $219.8M | $245.5M | $281.8M | $330.4M | $384.1M | $36.1M | $77,000 |
| Net debt | −$218.3M | −$243.1M | −$278.7M | −$326.7M | −$380.4M | −$36.1M | $618,000 |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — |
| Debt / assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | 7.72 |
| Current ratio | 17.14 | 29.31 | 29.58 | 31.10 | 72.96 | 15.55 | 0.02 |
| Quick ratio | 17.14 | 29.31 | 29.58 | 31.20 | 72.72 | 15.50 | 0.02 |
| Interest coverage | — | — | — | -14.4 | -120.2 | — | — |
| Working capital | $210.7M | $239.6M | $275.0M | $324.3M | $380.2M | $33.9M | −$3.6M |
| Invested capital | −$5.8M | −$1.0M | −$1.1M | $614,000 | $1.7M | −$47.4M | −$3.0M |
| Tangible asset value | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M | −$11.3M | −$3.6M |
| Net current asset value | $210.1M | $238.0M | $272.6M | $321.3M | $377.0M | −$11.6M | −$3.6M |
| Graham net-net per share | $3.62 | $4.18 | $4.84 | $5.69 | $8.19 | −$0.43 | −$0.13 |
| Capital allocation | |||||||
| Share buybacks (net) | $0 | $0 | $0 | $0 | $0 | — | — |
| Capex / revenue | — | — | — | — | — | 33,628.3% | 9.1% |
| Capex / depreciation | 0.31 | 0.57 | 0.48 | 2.26 | 11.92 | 15.20 | 0.04 |
| Stock-based compensation / revenue | — | — | — | — | — | 199,115.0% | 0.0% |
| R&D / revenue | — | — | — | — | — | 2,681,415.9% | 198.3% |
| SG&A / revenue | — | — | — | — | — | 1,104,424.8% | 130.5% |
| Efficiency | |||||||
| Days sales outstanding | — | — | — | — | — | 16,150.4 | — |
| Days of inventory on hand | — | — | — | 54.4 | 1,925.4 | 7,811.0 | — |
| Days payables outstanding | 1,319.8 | 1,263.4 | 1,687.4 | 1,819.1 | 4,271.1 | 141,547.0 | 547,058.6 |
| Cash conversion cycle (days) | — | — | — | — | — | -117,585.6 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | — |
| Payables turnover | 0.28 | 0.29 | 0.22 | 0.20 | 0.09 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | — | 0.19 | 0.05 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.27 |
| Average receivables | $1.5M | $1.3M | $1.3M | $612,500 | $60,000 | $10,000 | — |
| Average payables | $2.2M | $2.1M | $2.5M | $2.3M | $1.5M | $1.9M | $2.5M |
| Average inventory | — | — | — | $69,500 | $680,500 | $107,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DSGN's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DSGN valuation and financial ratios
Design Therapeutics earned a return on equity of −30.7% in fiscal 2025. It ended the year with $1.5 million of debt and $219.8 million in cash and short-term investments, a net cash position of $218.3 million. The share count rose 110.9% from 27.2M to 57.3M over 6 years.
See the DSGN income statement, the DSGN chart for price history, or the DSGN stock overview for the latest quote and news.
DSGN key metrics FAQ
What is Design Therapeutics's return on equity?
Design Therapeutics's return on equity (ROE) was −30.7% in fiscal 2025: net income of -$69.8 million on average shareholders' equity of $227.3 million.
How much debt does Design Therapeutics have?
Design Therapeutics had total debt of $1.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Design Therapeutics's free cash flow yield?
Design Therapeutics generated -$54.6 million of free cash flow in fiscal 2025, a free cash flow yield of −10.1% on its market value at year-end ($537.8 million).
What is Design Therapeutics's current ratio?
Design Therapeutics's current ratio was 17.14 at the end of fiscal 2025: current assets were 17.14 times current liabilities.